the GLP-1 Game Changers

Novo Nordisk | Semaglutide

Novo Nordisk launched Ozempic and Wegovy, pioneering GLP-1 therapy for weight loss, type 2 diabetes, and cardiovascular and kidney risks.

Semaglutide Details

Eli Lilly | Tirzepatide

The company behind Mounjaro and Zepbound, Eli Lilly is redefining treatment for obesity, type 2 diabetes, and now obstructive sleep apnea.

Tirzepatide Details

The Race for Third

With Novo Nordisk and Lilly leading the way, drugmakers like Amgen, Pfizer, and smaller biotechs are developing the next wave of GLP-1 innovations.

Oral GLP-1 Update

What Is GLP-1?

Understanding the science and sensational response

GLP-1 is a naturally occurring hormone that helps regulate appetite, blood sugar, and digestion. The medications you hear about today — like Ozempic, Wegovy, and Zepbound — are GLP-1 receptor agonists, meaning they mimic this hormone to enhance its effects. Some of the newest drugs, like tirzepatide, go even further by activating a second hormone pathway (GIP), making them dual agonists.

Even though these medications vary in mechanism, they’re all commonly referred to as “GLP-1s.” That nickname has become shorthand for an entire class of next-generation metabolic treatments that are rapidly reshaping how we think about obesity, diabetes, and even food addiction.

In Depth GLP-1 Details